Exocrine Pancreatic Insufficiency Treatment Market - By Treatment (Nutritional Management, Pancreatic Enzyme Replacement Therapy), Drug Type (Creon, Zenpep, Pancreaze, Ultresa, Viokace), Indication, Distribution Channel - Global Forecast (2024

Description

Exocrine Pancreatic Insufficiency Treatment Market size is set to record 6.6% CAGR from 2024 to 2032 due to the rising geriatric population. Lately, clinicians are developing and refining therapies to improve digestive enzyme supplementation for better nutrient absorption. These treatments help to alleviate symptoms, such as malnutrition and gastrointestinal discomfort in elderly patients.

Lately, the ongoing research is enhancing enzyme formulations and delivery methods to personalize enzyme therapies tailored to individual patient needs as well as improved diagnostic tools for early detection and management of exocrine pancreatic insufficiency (EPI)-related complications. The World Population Prospects 2022 highlighted a faster growth rate among the population aged 65 years and older compared to younger age groups. This trend is underscoring the heightened emphasis on improving treatment for exocrine pancreatic insufficiency to better address the health needs of the elderly.

The exocrine pancreatic insufficiency treatment industry is segmented into treatment, drug type, indication, distribution channel, and region.

The market share from the nutritional management treatment segment will record a decent growth rate between 2024 and 2032. This treatment method involves tailoring diets and enzyme replacement therapies to individual patient needs to optimize nutrient absorption and alleviate symptoms like malnutrition and digestive discomfort. Specialists are refining these approaches for integrating dietary adjustments with enzyme supplements to enhance efficacy and patient well-being. Additionally, research efforts are leading to more targeted therapies with optimized treatment protocols to improve patient outcomes and quality of life.

In terms of distribution channels, the EPI treatment market from the online pharmacies segment is anticipated to witness a significant CAGR from 2024-2032. This is driven by the easy access to treatments for providing a convenient platform for patients to order prescription medications and enzyme supplements necessary for managing symptoms, such as malabsorption and digestive issues. Pharmacists and healthcare providers are actively leveraging these platforms to ensure timely delivery and patient education on treatment adherence.

Asia Pacific exocrine pancreatic insufficiency treatment industry size will record significant CAGR through 2032 due to improving healthcare infrastructure and ongoing drug development and innovation efforts. Healthcare facilities are actively upgraded to better diagnose and manage EPI for providing enhanced access to necessary medications and therapies. Researchers and pharmaceutical companies are developing new drugs and treatment protocols to improve efficacy and patient outcomes. Ongoing innovations in drug delivery systems and therapeutic approaches are ensuring that EPI patients in Asia Pacific receive state-of-the-art care with improved quality of life for individuals living with pancreatic insufficiency across the region.

Product Code: 9379

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.2 Increasing prevalence of chronic pancreatitis (CP) and cystic fibrosis
- 3.2.3 Growing aging population
- 3.2.4 Advancements in diagnosis
- 3.2.5 Technological advancements in pharmaceutical industry
- 3.2.6 Industry pitfalls & challenges
- 3.2.7 High cost of treatment
- 3.2.8 Limited awareness and education
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Pipeline analysis
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Nutritional management
5.3 Pancreatic enzyme replacement therapy (PERT)

Chapter 6 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Creon
6.3 Zenpep
6.4 Pancreaze
6.5 Ultresa
6.6 Viokace
6.7 Other drug types

Chapter 7 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Abdominal pain
7.3 Constipation
7.4 Diarrhea
7.5 Fatty stools
7.6 Weight loss
7.7 Other indications

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

10.1 Abbott Laboratories
10.2 AbbVie Inc.
10.3 Allergan plc
10.4 Alexion Pharmaceuticals, Inc.
10.5 Anthera Pharmaceuticals Inc.
10.6 Amgen Inc.
10.7 AstraZeneca Plc
10.8 BioMarin Pharmaceutical Inc.
10.9 Cilian AG
10.10 Digestive Care, Inc.
10.11 Eli Lilly and Company
10.12 Johnson & Johnson
10.13 Nordmark Arzneimittel GmbH & Co. KG
10.14 Sanofi
10.15 Takeda Pharmaceutical Company Limited

Exocrine Pancreatic Insufficiency Treatment Market - By Treatment (Nutritional Management, Pancreatic Enzyme Replacement Therapy), Drug Type (Creon, Zenpep, Pancreaze, Ultresa, Viokace), Indication, Distribution Channel - Global Forecast (2024 - 2032)